Barclays analyst Gena Wang raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $78 from $58 to reflect enhanced conviction on Tryngolza, while keeping an Overweight rating on the shares after the company announced that its Phase 3 CORE/CORE2 met primary endpoint of TG reduction. Importantly, Tryngolza hit statistical significance of acute pancreatitis with impressive reduction of 85%. The firm expects large uptake in sHTG per its key opinion leaders’ feedback.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Buy Rating Backed by Promising Phase 3 Study Results for Olezarsen
- Morgan Stanley ups Ionis target on ‘best-case scenario’ data
- Ionis Pharmaceuticals price target raised to $70 from $55 at Needham
- Ionis Pharmaceuticals rises 31.2%
- Ionis Pharmaceuticals’ Olezarsen Triumphs in Phase 3 Trials, Analyst Raises Price Target